504 related articles for article (PubMed ID: 33779246)
1. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
Palli SR; Zhou S; Shaikh A; Willey VJ
J Manag Care Spec Pharm; 2021 May; 27(5):625-637. PubMed ID: 33779246
[No Abstract] [Full Text] [Related]
2. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
[TBL] [Abstract][Full Text] [Related]
3. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
Sethi S; Palli SR; Bengtson LGS; Buysman EK; Clark B; Sargent A; Shaikh A; Ferguson GT
J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
[No Abstract] [Full Text] [Related]
5. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
[No Abstract] [Full Text] [Related]
6. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
[TBL] [Abstract][Full Text] [Related]
7. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
[TBL] [Abstract][Full Text] [Related]
8. Health Plan Enrollment and Disenrollment of Individuals With and Without Established Chronic Disease in a U.S. Commercially Insured and Medicare Advantage Population.
Chung H; Deshpande G; Zolotarjova J; Quimbo RA; Kern DM; Cochetti PT; Willey VJ
J Manag Care Spec Pharm; 2019 May; 25(5):612-620. PubMed ID: 31039058
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Appropriate Pharmacotherapy Management of COPD Exacerbations and Impact on 6-Month Readmission.
Tran M; Xiang P; Rascati KL; Stock EM; Godley PJ; Coleman A; Bogart MR; Stanford RH
J Manag Care Spec Pharm; 2016 Oct; 22(10):1186-93. PubMed ID: 27668567
[TBL] [Abstract][Full Text] [Related]
10. Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
Slade D; Ray R; Moretz C; Germain G; Laliberté F; Shen Q; Duh MS; Mahendran M; Hahn B
BMC Pulm Med; 2021 Jul; 21(1):253. PubMed ID: 34332555
[TBL] [Abstract][Full Text] [Related]
11. Inhaled Corticosteroid-Containing Treatment Escalation and Outcomes for Patients with Asthma in a U.S. Health Care Organization.
Bengtson LGS; Yu Y; Wang W; Cao F; Hulbert EM; Wolbeck R; Elliott CA; Buikema AR
J Manag Care Spec Pharm; 2017 Nov; 23(11):1149-1159. PubMed ID: 29083972
[TBL] [Abstract][Full Text] [Related]
12. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
13. Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England.
Sansbury LB; Rothnie KJ; Bains C; Compton C; Anley G; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2021; 16():2591-2604. PubMed ID: 34552325
[TBL] [Abstract][Full Text] [Related]
14. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
Stanford RH; Parker ED; Reinsch TK; Buikema AR; Blauer-Peterson C
Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
[TBL] [Abstract][Full Text] [Related]
15. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
[TBL] [Abstract][Full Text] [Related]
16. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers.
Singer D; Bengtson LGS; Elliott C; Buikema AR; Franchino-Elder J
Int J Chron Obstruct Pulmon Dis; 2020; 15():3239-3250. PubMed ID: 33324047
[TBL] [Abstract][Full Text] [Related]
17. External Validation of a COPD Risk Measure in a Commercial and Medicare Population: The COPD Treatment Ratio.
Stanford RH; Lau MS; Li Y; Stemkowski S
J Manag Care Spec Pharm; 2019 Jan; 25(1):58-69. PubMed ID: 30589629
[TBL] [Abstract][Full Text] [Related]
18. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
[TBL] [Abstract][Full Text] [Related]
19. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.
Price D; West D; Brusselle G; Gruffydd-Jones K; Jones R; Miravitlles M; Rossi A; Hutton C; Ashton VL; Stewart R; Bichel K
Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450
[TBL] [Abstract][Full Text] [Related]
20. Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD).
Chalmers JD; Poole C; Webster S; Tebboth A; Dickinson S; Gayle A
Respir Res; 2018 Apr; 19(1):63. PubMed ID: 29642882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
